Gene therapies, despite of being a relatively new therapeutic approach, have a potential to
become an important alternative to current treatment strategies in glaucoma. Since …

Gene therapies, despite of being a relatively new therapeutic approach, have a potential to
become an important alternative to current treatment strategies in glaucoma. Since …

In recent years, much progress has been made in the identification of the genes involved in
the physiology of glaucoma and the development of new gene‐based therapies. The …

Glaucoma leads to irreversible vision loss and current therapeutic strategies are often
insufficient to prevent the progression of the disease and consequent blindness. Elevated …

The prevalence of glaucoma, the second leading cause of global blindness, is increasing
due to aging populations. In glaucoma, degeneration of the optic nerve and retinal ganglion …

Glaucoma is a chronic and multifactorial neurodegenerative disease marked by structural
damage to the optic nerve with axonal loss, progressive retinal ganglion cell degeneration …

Gene therapy for glaucoma : Current Opinion in Ophthalmology Gene therapy for glaucoma :
Current Opinion in Ophthalmology Log in or Register Subscribe to journalSubscribe Get new …

Glaucoma is the result of the gradual death of retinal ganglion cells (RGCs) whose axons
form the optic nerve. Elevated intraocular pressure (IOP) is a major risk factors …

Glaucoma is a group of diseases typically characterized by the degeneration of the optic
nerve and is one of the world's leading causes of blindness. Although there is no cure for …

Glaucoma is a leading cause of irreversible visual impairment and blindness worldwide.
Although it has been well established that neurodegeneration plays a key role in the …